Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer.
about
Era of universal testing of microsatellite instability in colorectal cancerPhenotypic and tumor molecular characterization of colorectal cancer in relation to a susceptibility SMAD7 variant associated with survivalEGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndromeDetection of BRAF V600E mutation in colorectal cancer: comparison of automatic sequencing and real-time chemistry methodologyMolecular models for the tissue specificity of DNA mismatch repair-deficient carcinogenesisHow do we approach the goal of identifying everybody with Lynch syndrome?Observational Study: Familial Relevance and Oncological Significance of Revised Bethesda Guidelines in Colorectal Patients That Have Undergone Curative ResectionDevelopment and validation of a colon cancer risk assessment tool for patients undergoing colonoscopy.Detection of mismatch repair gene germline mutation carrier among Chinese population with colorectal cancerAberrant gene promoter methylation associated with sporadic multiple colorectal cancerDefective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer.Comprehensive population-wide analysis of Lynch syndrome in Iceland reveals founder mutations in MSH6 and PMS2.Performance of clinical guidelines compared with molecular tumour screening methods in identifying possible Lynch syndrome among colorectal cancer patients: a Norwegian population-based studyColorectal cancer prognosis twenty years later.Utility of p16 immunohistochemistry for the identification of Lynch syndromeColorectal cancer: from prevention to personalized medicine.Current and emerging trends in Lynch syndrome identification in women with endometrial cancer.Predictive model for high-frequency microsatellite instability in colorectal cancer patients over 50 years of age.Evidence for classification of c.1852_1853AA>GC in MLH1 as a neutral variant for Lynch syndromeMismatch repair protein expression and colorectal cancer in Hispanics from Puerto RicoLower gastrointestinal tract cancer predisposition syndromesMethylation analysis of MLH1 improves the selection of patients for genetic testing in Lynch syndrome.A two-phase case-control study for colorectal cancer genetic susceptibility: candidate genes from chromosomal regions 9q22 and 3q22.Case-control study for colorectal cancer genetic susceptibility in EPICOLON: previously identified variants and mucins.Clinical relevance of microsatellite instability in colorectal cancer.Transketolase-like 1 expression is modulated during colorectal cancer progression and metastasis formationIGFBP3 methylation is a novel diagnostic and predictive biomarker in colorectal cancer.Genetic associations in the vitamin D receptor and colorectal cancer in African Americans and Caucasians.Mismatch repair deficiency endows tumors with a unique mutation signature and sensitivity to DNA double-strand breaks.A novel pathogenic MLH1 missense mutation, c.112A > C, p.Asn38His, in six families with Lynch syndrome.Application of molecular diagnostics for the detection of Lynch syndrome.Single nucleotide polymorphisms in the Wnt and BMP pathways and colorectal cancer risk in a Spanish cohort.Early-onset colorectal cancer: a sporadic or inherited disease?Microsatellite instability among individuals of Hispanic origin with colorectal cancerEPCAM germ line deletions as causes of Lynch syndrome in Spanish patientsTumor characteristics as an analytic tool for classifying genetic variants of uncertain clinical significance.Clinical problems of colorectal cancer and endometrial cancer cases with unknown cause of tumor mismatch repair deficiency (suspected Lynch syndrome)The revised Bethesda guidelines: extent of utilization in a university hospital medical center with a cancer genetics programA high degree of LINE-1 hypomethylation is a unique feature of early-onset colorectal cancer.MSH6 and MUTYH deficiency is a frequent event in early-onset colorectal cancer
P2860
Q24596823-5B018275-0023-4DAC-986D-8BF70A45B168Q24626799-EAAEB27F-8EBE-4BAD-9874-020653698FC8Q24655053-8669796D-D050-4CA7-BE72-A19FCCDA2292Q24681980-77557FEB-3B59-464F-BAAC-CB9597164A52Q25257401-64597BBF-EA9F-4E71-B177-8981775ECAF6Q26865836-724F153D-EB3C-44BF-9048-56A6A2D398EDQ27315851-42EB7166-3BD0-4EED-9CED-2A4EEE38FB21Q30484158-3307A760-8282-45E3-AFF4-82D6503EF058Q33318711-6C461360-40B2-4331-B168-9CF7C09AA1CFQ33526369-9C812740-49CB-412A-B107-5F99A4F00CD2Q33586020-B3E7F8FA-CF96-4C13-9AAC-A107ECE80E56Q33640008-008DAEEE-8131-4158-85FB-29F015E273A5Q33658603-CCBE988C-9B96-4CAD-8370-892CF733D40CQ33672866-A311A0DE-DBCA-4C08-948A-5CEBBFA7364CQ33675252-6FBFA328-9787-408F-91CD-E121D6853A56Q33735234-79EDC193-CF34-4F6C-999A-A38DA8C67638Q33738168-6910EB10-3B11-4626-9B12-1D402BD8AD29Q33775336-BB19026F-AFFC-426C-8027-9E274B81C1C8Q33797266-F5F01852-5B89-4EA8-9A54-0327F929DD92Q33862772-71CDD996-8F97-45B8-8A7E-986BFE02F337Q33920573-B7954275-3B2E-4B1B-BD52-17064D29F167Q33947093-22A421DB-67C7-406B-A5D3-AC074886A798Q33979369-4A81C8DD-78D0-4384-84EF-E18B5F8DB929Q33983942-89AE5596-2B15-4788-A9A8-51B4CDF57A85Q33990921-DEE968E1-2A19-493E-B9FB-D4E795FA7459Q34043101-C12748C4-844B-4A2D-8431-ED7188EA033DQ34050656-263D71FD-6C58-4FE6-83A8-B934E52DBCC7Q34064357-D87DC4D3-A6E1-4D16-8F65-DA2283A77EEEQ34077139-76C756A3-9117-4D03-B8A3-9D8DF34CCA0DQ34081661-A0A63A9B-BC4C-4AA7-947D-448B6665E1CEQ34088809-A6B0B404-849C-481A-B74D-D72B766CAD81Q34115361-E759F7DF-BEF4-40CC-BC9D-DE3F23213324Q34207783-4A8A086B-02A9-439C-8BD6-7416C5F99A40Q34238514-3A1D4B9E-70F6-40B6-9E23-A398679B21E7Q34239731-43468789-D5CC-459B-8B73-6141B3A2C6DDQ34252077-4C8C5F93-9E42-4CA5-B951-282847A83402Q34351784-33F76325-28FB-4742-A277-BB143F7A2124Q34380045-8CFACF46-25FB-419B-95D4-9EC67389BD12Q34438078-75E3CE62-2ACB-498A-8187-2A12AE1EE93EQ34545271-84CB4DB8-0EA6-419A-AB38-63A2E8AD5AB0
P2860
Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer.
description
2005 nî lūn-bûn
@nan
2005 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Accuracy of revised Bethesda g ...... onpolyposis colorectal cancer.
@ast
Accuracy of revised Bethesda g ...... onpolyposis colorectal cancer.
@en
Accuracy of revised Bethesda g ...... onpolyposis colorectal cancer.
@nl
type
label
Accuracy of revised Bethesda g ...... onpolyposis colorectal cancer.
@ast
Accuracy of revised Bethesda g ...... onpolyposis colorectal cancer.
@en
Accuracy of revised Bethesda g ...... onpolyposis colorectal cancer.
@nl
prefLabel
Accuracy of revised Bethesda g ...... onpolyposis colorectal cancer.
@ast
Accuracy of revised Bethesda g ...... onpolyposis colorectal cancer.
@en
Accuracy of revised Bethesda g ...... onpolyposis colorectal cancer.
@nl
P2093
P921
P356
P1476
Accuracy of revised Bethesda g ...... nonpolyposis colorectal cancer
@en
P2093
Artemio Payá
Cristina Alenda
Gastrointestinal Oncology Group of the Spanish Gastroenterological Association
Montserrat Andreu
Rodrigo Jover
Rosa M Xicola
Sergi Castellví-Bel
Virgínia Piñol
Xavier Bessa
Xavier Llor
P304
P356
10.1001/JAMA.293.16.1986
P407
P577
2005-04-01T00:00:00Z